Government Action

FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference

Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The

Read More »

UK Antibiotic Subscription Pilot implies Pull Incentive of up to $4b across the G20

Note that there is a follow-up newsletter that covers a post-webinar FAQ. After reading this newsletter as introduction, please go here for the follow-up newsletter. Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Prior newsletters have covered the antibiotic evaluation procurement pilot being run by NICE and NHS England (go here for the

Read More »

FORWARD Act, PREVENT Act, new NIAID RFP!

Dear All, Our US government colleagues have been busy! Three things back-to-back: First, the FORWARD Act (Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2022”) was introduced in the US Senate on 13 Jan 2021 as S.3498 by Sens. Kelly, Sinema, and Feinstein. You’ve got to admire the acronymics! The Senate bill is the

Read More »

$50-100k grants to address socioeconomic outcome disparities due to AMR-related factors

Dear All, I was fascinated to see Mayo Clinic’s Global Bridges Healthcare Alliance release an RFP on 21 Oct entitled “Antimicrobial Stewardship (AMS) Programs to Address Health Inequities arising from Socioeconomic Disparities in USA, Europe, Japan, South Korea, Australia and New Zealand.” The RFP is supported by a grant from Pfizer and seeks to “… solicit programs that have

Read More »

Support the FORWARD and PASTEUR Acts by signing a letter!

Dear All, I’ve written before about the FORWARD Act, a bill introduced last year into Congress with the goal of supporting research in to treatment of endemic fungal diseases with a particular focus on coccidioidomycosis (*). It’s easy to see how this bill and the PASTEUR Act are mutually supportive … both seek to build

Read More »

WHO Forming Task Force of Antimicrobial Resistance Survivors

Dear All, The WHO has announced a call for expressions of interests from AMR survivors and their caregivers to serve in the inaugural WHO Task Force of AMR Survivors! WHO are specifically looking for both (i) survivors of a drug-resistant infection and (ii) anyone who was a direct caregiver of such a patient. Their goal is

Read More »

ARPEGE: New €17m French Consortium tackles economics, diagnostics, and therapeutics

Dear All, On 6 Jan 2022, we had the announcement of the creation of in France of the ARPEGE consortium (AppRoche théraPeutique Economique & diaGnostique de l’antibiorésistancE) or “Economic, diagnostic and therapeutic approach to antibiotic resistance.” Somebody definitely had fun with that acronym! Here’s what you need to know: The French government is providing €9m of

Read More »

21st Century Cures v2.0 — PASTEUR Act is embedded!

Dear All, Building on the success of the 21st Century Cures Act passed in 2016 and springboarding from a concept paper published in Science, U.S. Reps. Diana DeGette, D-Colorado, and Fred Upton, R-Michigan, have today introduced the 21st Century Cures Act v2.0! Here are the links you need: Discussion draft of the Cures 2.0 bill Cures 2.0

Read More »

16 Positions Available at PACCARB! Apply Now!

Dear All, The US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) has announced it is looking for new members! As a reminder, PACCARB was founded in 2014 and is the advisory body for the US National Action Plan for Combating Antimicrobial Bacteria. The first National Action Plan ran from 2015 to 2020 and the second

Read More »
Scroll to Top